Inflammation Research

, Volume 44, Supplement 2, pp S179–S180 | Cite as

Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes

  • C. C. Bansbach
  • D. Wancio
  • S. N. Sehgal
VI. Lymphocyte activation/immunoregulation


Protein Synthesis Rapamycin Sirolimus Primary Lymphocyte 


  1. [1]
    Sehgal SN, Bansbach CC. Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann of NY Academy Sciences 1993;685:58–67.Google Scholar
  2. [2]
    Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992;69:1227–36.PubMedGoogle Scholar
  3. [3]
    Kuo CJ, Chung J, Florentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;358:70–3.PubMedGoogle Scholar
  4. [4]
    Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992;257:973–7.PubMedGoogle Scholar
  5. [5]
    Terada N, Lucas JJ, Szepesi A, Franklin RA, Takase K, Gelfand EW. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem Biophys Res Commun 1992;186:1315–21.PubMedGoogle Scholar
  6. [6]
    Jefferies HBJ, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the “polypyrimidine tract” mRNA family. Proc Natl Acad Sci 1994;91:4441–5.Google Scholar
  7. [7]
    Bansbach CC, Casilio-Lonardo E, Adams LM, Sehgal SN, Chang JY. Inhibition of human lymphocyte proliferation by rapamycin, a novel immunosuppressant, FASEB J 4:A1768.Google Scholar

Copyright information

© Birkhäuser Verlag 1995

Authors and Affiliations

  • C. C. Bansbach
    • 1
  • D. Wancio
    • 1
  • S. N. Sehgal
    • 1
  1. 1.Wyeth-Ayerst ResearchPrincetonUSA

Personalised recommendations